Search Results - "Berton-Rigaud, D"

549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study.

Authors: André, T. Berton-Rigaud, D. Curigliano, G. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS799-S800. 2p.

755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H).

Authors: Berton-Rigaud, D. Pautier, P. Lorusso, D. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS517-S517. 1p.

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.

Authors: Gernier, F. Gompel, A. Rousset-Jablonski, C. et al.

Source: Gynecologic Oncology. Dec2021, Vol. 163 Issue 3, p598-604. 7p.

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

Authors: Campone, M. Levy, V. Bourbouloux, E. et al.

Source: British Journal of Cancer. 1/27/2009, Vol. 100 Issue 2, p315-321. 7p. 4 Charts, 1 Graph.

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.

Authors: Loussouarn, D. Campion, L. Sagan, C. et al.

Source: British Journal of Cancer. 6/17/2008, Vol. 98 Issue 12, p1993-1998. 6p. 1 Color Photograph, 3 Charts, 2 Graphs.

1142P Dynamics and prognostic impact of HER3 expression in advanced ovarian cancer treated with neoadjuvant chemotherapy: Results from the CHIVA GINECO study.

Authors: Diaz, B.L. Alvarez Genestie, C. Blanc-Durand, F. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS757-S757. 1p.

1131P Upgrading the performance of ECOG performance status in recurrent ovarian cancer (ECOG+).

Authors: Pitiyarachchi, O. Sim, H-W. OConnell, R. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS752-S752. 1p.

813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial.

Authors: Frenel, J-S. Kim, J-W. Berton-Rigaud, D. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS615-S615. 1p.

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

Authors: Mirza, Mansoor R. Benigno, B. Dørum, A. et al.

Source: Gynecologic Oncology. Nov2020, Vol. 159 Issue 2, p442-448. 7p.

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

Authors: Derquin, F. Floquet, A. Hardy-Bessard, A.C. et al.

Source: Gynecologic Oncology. Sep2020, Vol. 158 Issue 3, p666-672. 7p.

Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.

Authors: Joly, F Ahmed-Lecheheb, D Kalbacher, E et al.

Source: Annals of Oncology. May2019, Vol. 30 Issue 5, p845-852. 8p. 1 Diagram, 4 Charts.

815P Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study.

Authors: Alexandre, J. Boudier, P. Kalbacher, E. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS539-S540. 2p.

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

Authors: Poveda, A. del Campo, J. M. Ray-Coquard, I. et al.

Source: Annals of Oncology. Jun2017, Vol. 28 Issue 6, p1280-1287. 8p. 4 Charts, 1 Graph.

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.

Authors: Heudel, P-E Fabbro, M Roemer-Becuwe, C et al.

Source: British Journal of Cancer. 1/31/2017, Vol. 116 Issue 3, p303-309. 7p. 4 Charts, 1 Graph.

528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?

Authors: Thibault, G. Kfoury, M. Lorusso, D. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS787-S788. 2p.

535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study.

Authors: Joly Lobbedez, F. Ray-Coquard, I.L. Lefevre Arbogast, S. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS792-S793. 2p.

A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.

Authors: Selle, F. Sevin, E. Ray-Coquard, I. et al.

Source: Annals of Oncology. Nov2014, Vol. 25 Issue 11, p2191-2196. 6p. 3 Charts, 1 Graph.

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.

Authors: Lee, C. K. Simes, R. J. Brown, C. et al.

Source: Annals of Oncology. Apr2013, Vol. 24 Issue 4, p937-943. 7p.

827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc).

Authors: Bellier, C. Gladieff, L. Le Du, F. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS623-S624. 2p.

1577P Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus.

Authors: Selle, F. Scotté, F. Boffa, J-J. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1267-S1267. 1p.